1/14
Why doesn& #39;t daptomycin treat pneumonia?

The answer also explains why dapto raises serum CK levels.

#medtwitter #tweetorial
3/
What about lung infections in humans?

Compared to ceftriaxone,  daptomycin had lower cure rates for treatment of community acquired pneumonia (CAP).

https://pubmed.ncbi.nlm.nih.gov/18444848/ ">https://pubmed.ncbi.nlm.nih.gov/18444848/...
5/
As a lipopeptide with a fat-soluble tail, daptomycin inserts into bacterial membranes (and cell walls) in the presence of calcium.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC171788/">https://www.ncbi.nlm.nih.gov/pmc/artic...
6/
Once inserted into a bacterium& #39;s cellular membrane, daptomycin disrupts its integrity.

https://abs.twimg.com/emoji/v2/... draggable="false" alt="🔑" title="Schlüssel" aria-label="Emoji: Schlüssel"> This disruption leads to K+ efflux out of the cell and loss of membrane potential, which causes failure of cellular machinery and eventually cell death.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC166110/">https://www.ncbi.nlm.nih.gov/pmc/artic...
7/
Now that we understand how daptomycin works, let& #39;s learn why it doesn& #39;t work in the lungs.

You may have heard that it has something to do with pulmonary surfactant...
8/
(Very) brief pulmonary surfactant review:

Surfactant, similar to daptomycin, is a lipoprotein with fat and water soluble components. It reduces surface tension at the air-liquid interface in the lung and prevents alveolar collapse.

https://pubmed.ncbi.nlm.nih.gov/30552091/ ">https://pubmed.ncbi.nlm.nih.gov/30552091/...
9/
It turns out that adding surfactant to daptomycin in vitro leads to almost immediate loss of antibacterial activity.

https://pubmed.ncbi.nlm.nih.gov/15898002/ ">https://pubmed.ncbi.nlm.nih.gov/15898002/...
11/
We are left with the mechanism for why daptomycin is ineffective in the lungs:

Pulmonary surfactant sequesters dapto via its hydrophobic tail. This prevents access to bacterial membranes.

https://abs.twimg.com/emoji/v2/... draggable="false" alt="🔑" title="Schlüssel" aria-label="Emoji: Schlüssel"> In effect, daptomycin& #39;s very mechanism of action precludes treatment of pneumonia.
12/
A final interesting correlate:

Creatine kinase (CK) elevation, and even skeletal muscle myopathy, are known complications of daptomycin therapy.

Can you think of how this might relate to its mechanism of action?
13/
While the cause isn& #39;t definitively known, serum CK elevation is thought to result from daptomycin-induced disruption of skeletal muscle membranes.

This is the exact same type of membrane damage that causes bacterial killing.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101585/">https://www.ncbi.nlm.nih.gov/pmc/artic...
14/
https://abs.twimg.com/emoji/v2/... draggable="false" alt="💡" title="Elektrische Glühbirne" aria-label="Emoji: Elektrische Glühbirne">Daptomycin disrupts bacterial membranes via a fat-soluble “tail”
https://abs.twimg.com/emoji/v2/... draggable="false" alt="💡" title="Elektrische Glühbirne" aria-label="Emoji: Elektrische Glühbirne">It’s ineffective in lung infections b/c pulmonary surfactant traps it in lipid aggregates
https://abs.twimg.com/emoji/v2/... draggable="false" alt="💡" title="Elektrische Glühbirne" aria-label="Emoji: Elektrische Glühbirne">Serum CK elevation likely results from the same mechanism (impacts on integrity of skeletal muscle membranes)
You can follow @AvrahamCooperMD.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: